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BACKGROUND: The frequency of the initial short-term decline in estimated glomerular filtration rate (eGFR), eGFR dip, following
initiation of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and its clinical implications in real-world practice are not clear.

Downloaded from http://ahajournals.org by on September 13, 2021

METHODS AND RESULTS: We built a cohort of 36 638 new users of SGLT2i and 209 025 new users of other antihyperglycemics.
Inverse probability weighting was used to estimate the excess rate of eGFR dip, risk of the composite cardiovascular outcome
of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, or all-cause mortality, and risk of the composite kidney outcome of eGFR decline >50%, end-stage kidney disease, or all-cause mortality. In the first 6 months of therapy,
compared with other antihyperglycemics, excess rates of eGFR dip >10% and eGFR dip >30% were 9.86 (95% CI: 8.83–11.00)
and 1.15 (0.70–1.62) per 100 SGLT2i users, respectively. In mediation analyses that accounted for eGFR dipping, SGLT2i use
was associated with reduced risk of cardiovascular and kidney outcomes (hazard ratio, 0.92 [0.84–0.99] and 0.78 [0.71–0.87],
respectively); the magnitude of the association reduced by eGFR dipping was small for both outcomes. SGLT2i was associated with reduced risk of both outcomes in those with higher than average probability of eGFR dip >10% or 30%. Compared
with discontinuation, continued use of SGLT2i at 6 months was associated with reduced risk of cardiovascular and kidney
outcomes in those with no eGFR dip or eGFR dip ≤10%, in those with eGFR dip >10%, and in those with eGFR dip >30%.
CONCLUSIONS: The salutary association of SGLT2i with cardiovascular and kidney outcomes was maintained regardless of
eGFR dipping; concerns about eGFR dipping should not preclude use, and occurrence of eGFR dip after SGLT2i initiation
may not warrant discontinuation.
Key Words: cardiovascular outcomes ■ diabetes mellitus ■ estimated glomerular filtration rate ■ kidney ■ kidney function

■ kidney outcomes ■ sodium-glucose cotransporter-2 inhibitors

S

everal randomized clinical trials provided evidence
that sodium-
glucose cotransporter-
2 inhibitors
(SGLT2i) reduce the risk of major cardiovascular
and kidney outcomes in people with type 2 diabetes
mellitus.1–7 Evidence from recent trials suggests that
the salutary properties of SGLT2i may even extend to

people without diabetes mellitus.8–10 However, in several randomized trials, SGLT2i use was associated with
an initial estimated glomerular filtration rate (eGFR) decline, eGFR dip, within a few weeks and up to 6 months
following initiation of therapy.11 The eGFR dip is generally followed by recovery and stabilization during the
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CLINICAL PERSPECTIVE
What Is New?

• In the first 6 months of treatment, estimated glomerular filtration rate (eGFR) dipping was more
common among sodium-
glucose cotransporter-
2 inhibitor (SGLT2i) users than other
antihyperglycemics; however, most eGFR dips
were <30%.
• eGFR dipping did not abrogate the beneficial
association between SGLT2i and cardiovascular and kidney outcomes.
• Continued use of SGLT2i (versus discontinuation) was associated with reduced risk of cardiovascular and kidney outcomes regardless of
degree of eGFR dipping.

What Are the Clinical Implications?
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• Real-world effectiveness of SGLT2i on cardiovascular and kidney outcomes was maintained
regardless of eGFR dipping.
• Concern about dipping should not preclude
initiation of SGLT2i, and occurrence of an eGFR
dip following SGLT2i initiation should not, on its
own, motivate SGLT2i discontinuation.
• As a means of achieving longer-term reduction
in risk of cardiovascular and kidney outcomes,
practitioners may consider continuation of
treatment with SGLT2i regardless of eGFR
dipping.

subsequent months; in the long-term, SGLT2i use was
associated with relative eGFR preservation compared
with placebo.11
However, the frequency and extent of eGFR dip
in SGLT2i users relative to other antihyperglycemics,
whether eGFR dipping erodes SGLT2i effectiveness
on cardiovascular and kidney outcomes, and whether
eGFR dip is associated with increased risk of discontinuation of SGLT2i in real-world practice are not known.
Furthermore, whether continued SGLT2i use (versus
discontinuation) following an intervening SGLT2i dip
is associated with reduced risk of cardiovascular and
kidney outcomes is unknown. Addressing this knowledge gap will illuminate our understanding of the clinical ramifications of the eGFR dip in SGLT2i users.
Herein, we leveraged the breadth and depth of
the US Department of Veterans Affairs (VA) electronic
healthcare databases to build a cohort of 36 638 incident users of SGLT2i, and 209 025 incident users of
other antihyperglycemics, and aimed to characterize
the rates of eGFR dipping in each antihyperglycemic
group, identify characteristics associated with eGFR
dipping in SGLT2i users, examine whether and to what
extent the effectiveness of SGLT2i on cardiovascular
and kidney outcomes was abrogated by an intervening
eGFR dip, and finally evaluate the risk of major cardiovascular outcomes and kidney outcomes associated
with SGLT2i continuation versus discontinuation according to eGFR dipping category.

METHODS
Nonstandard Abbreviations and Acronyms
CDW
CREDENCE

EMPA-REG OUTCOME

SGLT2i

VA

Corporate Data
Warehouse
Evaluation of the
Effects of Canagliflozin
on Renal and
Cardiovascular
Outcomes in
Participants With
Diabetic Nephropathy
Empagliflozin
Cardiovascular
Outcome Event Trial in
Type 2 Diabetes
Mellitus Patients
sodium-glucose
cotransporter-2
inhibitor(s)
US Department of
Veterans Affairs

Because of the sensitive nature of the data used in this
study, the data sets could only be accessed after obtaining approval from the VA.

Cohort Design
Participants who received antihyperglycemic medication from the VA Health Care System between October
1, 2015, and July 31, 2019, were selected (n=1 293 984).
Participants were separated first into an SGLT2i group,
which included patients who received an SGLT2i prescription between October 1, 2016, and July 31, 2019
(n=59 133). The other antihyperglycemic group was
then selected from participants who did not receive
SGLT2i prescription between October 1, 2016, and July
31, 2019. The other antihyperglycemic group included
patients who either added on or switched from their
existing non-
SGLT2i antihyperglycemic medication to
a non-SGLT2i antihyperglycemic prescription between
October 1, 2016, and July 31, 2019 (n=423 193), where
the first date of meeting this criterion was considered
time of treatment initiation. In each group, participants without a history of SGLT2i exposure within the
1 year before treatment initiation were selected (SGLT2i
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group, n=55 466; and other antihyperglycemic group,
n=420 625). We further excluded participants with history of type 1 diabetes mellitus, those with end-stage
kidney disease, or those who were enrolled in the
healthcare system for <1 year at treatment initiation
(SGLT2i group, n=51 816; and other antihyperglycemic
group, n=387 467). Within participants who remained in
the cohort, 46 122 in the SGLT2i group and 312 794 in
the other antihyperglycemic group had measurements
of glycated hemoglobin (HbA1c), low-density lipoproteins, blood pressure, height, weight, and had eGFR
measurement ≥30 mL/min per 1.73 m2 within the 1 year
before treatment initiation. To evaluate the change in
eGFR within the first 6 months (180 days) after treatment
initiation, we removed participants who had no eGFR
measurement or who experienced the composite cardiovascular or kidney outcome in this time period (SGLT2i
group, n=36 638; and other antihyperglycemic group,
n=209 025). Participants were followed until the occurrence of an outcome or administrative end of followup (January 31, 2020). Informed consent was waived
for this study. The cohort flowchart is presented in
Figure S1, and study timeline is presented in Figure S2.

Data Sources
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Data from the VA Corporate Data Warehouse (CDW)
were used in this study.12–26 CDW Outpatient and
Inpatient Encounters domains included International
Classification of Diseases, Tenth Revision (ICD-10), diagnosis codes, ICD-10 procedure codes, and Current
Procedural Terminology codes.27 Medication prescriptions were obtained from the CDW Outpatient
Pharmacy domain. Laboratory measurements from the
CDW Laboratory Results domain were also collected
and used.28 The CDW Vital Signs domain provided vital
measurements, and the CDW Patient domain and VA
Vital Status provided demographic information.29

Exposure and Outcomes
Prescriptions of SGLT2i or other antihyperglycemic
medications were identified from outpatient pharmacy
records. The distribution of antihyperglycemic medications at treatment initiation is presented in Table S1.15,30
Differences in rates of eGFR dip >10% and >30%
between the SGLT2i and other antihyperglycemic
groups were examined. eGFR dip was evaluated on
the basis of the difference between baseline eGFR,
defined as the average eGFR within 1 year before
treatment initiation, and the lowest eGFR value measured within 6 months after the treatment initiation.
The difference was transformed into percentage
change compared with baseline eGFR. The CKD
Epidemiology Collaboration creatinine equation was
used to compute eGFR based on serum creatinine,
age, race, and sex.31

eGFR Dip in SGLT2i

SGLT2i discontinuation was defined as a >90-day
gap between the last supply date of a prescription and
the next prescription, where the date of the last supply
was within 6 months after treatment initiation. The associations between discontinuation of SGLT2i and the cardiovascular and kidney outcomes were examined. The
composite cardiovascular outcome was defined as nonfatal myocardial infarction, nonfatal stroke, hospitalization
for heart failure, or all-cause mortality. The composite
kidney outcome was defined as eGFR decline >50%
from treatment initiation, end-stage kidney disease, or
all-cause mortality. Time of end-stage kidney disease
was identified by first occurrence of eGFR <15 mL/min
per 1.73 m2, long-term dialysis, or kidney transplant.

Covariates
Baseline Covariates
Covariate selection was informed by prior knowledge.15,17,18,20,22,24,32 Covariates that may influence
antihyperglycemic prescription included age, race
(White, Black, and other, where other race included
non-White and non-Black participants), sex, HbA1c,
eGFR, systolic blood pressure, diastolic blood pressure, low-density lipoproteins, body mass index (computed from height and weight), smoking status (never,
former, or current), type of hospital system where the
antihyperglycemic was prescribed (outpatient clinic or
healthcare system), and the calendar year of enrollment. eGFR was the average eGFR within 1 year before treatment initiation. Clinical comorbidities, such as
congestive heart failure, cardiovascular diseases, cancer, alcoholism, hypoglycemia, diabetic ketoacidosis,
acute kidney injury, bladder and urinary tract infections,
venous thromboembolism, pancreatitis, bone fracture,
and albuminuria, were also included.33 Acute kidney
injury was defined as an increased serum creatinine
of 0.3 mg/dL or 50% within 30 days, and albuminuria
status was categorized into no albuminuria (≤30 mg/g),
microalbuminuria (>30–
≤300 mg/g), and macroalbuminuria (>300 mg/g). History use of glucagon-like
peptide 1 agonists, dipeptidyl peptidase-4 inhibitors,
sulfonylureas, thiazolidinediones, metformin, insulin, α-
glucosidase inhibitors, meglitinides, amylin analogues,
statins, angiotensin-
converting enzyme inhibitors or
angiotensin receptor blockers, β-blockers, loop diuretics, nonloop diuretics, and calcium channel blockers
was also used as covariates.33 Covariates were ascertained within the 1 year before the treatment initiation.
Characteristics Within 6 Months After
Treatment Initiation
To examine characteristics that may be associated with
SGLT2i discontinuation, we additionally evaluated the
occurrence of adverse events, including hypoglycemia,
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diabetic ketoacidosis, amputation, bladder and urinary
tract infections, venous thromboembolism, pancreatitis, bone fracture, hospitalizations that were not related
to adverse events, and HbA1c change (categorized
as increase or lack of increase in HbA1c) within the
6 months after treatment initiation.

Statistical Analysis
Characteristics of the cohort and by treatment group
and eGFR dip categories are presented as mean and
SD, or number and percentage, as appropriate. A schematic of the analytic approach is presented in Figure S3.
Rates of eGFR Dip and Predictors of the Dip
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Differences in rate of eGFR dips, including dip >10%
and dip >30%, between the SGLT2i group and other
antihyperglycemic group were examined by weighted
generalized estimating equations for logistic regression. To balance potential confounders between
treatments, inverse probability of treatment weighting method was applied.34 Probability of receiving
the assigned treatment at treatment initiation was
estimated from logistic regression based on covariates ascertained at treatment initiation. The inverse
probability of treatment weighting was then constructed as the inverse probability stabilized by the
prevalence of treatments at time of treatment initiation. The inverse probability of treatment weighting
was then truncated at the 0.1 and 99.9 percentiles
to further stabilize the weighting.35 Absolute rate per
100 patients in each group and the excess rates associated with SGLT2i were estimated on the basis
of the predicted probability. We additionally evaluated the excess rates in subgroups based on race,
eGFR category, and albuminuria category, and in
those with congestive heart failure and those using
angiotensin-
converting enzyme inhibitors/angiotensin receptor blockers, loop diuretics, and nonloop
diuretics. We also investigated the characteristics
that may be associated with eGFR dip >10% and dip
>30% in SGLT2i users using logistic regressions.
eGFR Dip and the Effectiveness of SGLT2i on
Cardiovascular and Kidney Outcomes
We evaluated the mediation effect of eGFR dip on the
associations between SGLT2i and composite cardiovascular and kidney outcomes through inverse odds
ratio (OR) weighting for causal mediation analysis.36 In
mediation analyses, we estimated the direct effect independent of eGFR dip >10% and, in separate analyses,
eGFR dip >30%. The total effect of SGLT2i, accounted
for eGFR dipping as a mediator was estimated from a
Cox model weighted by inverse probability of treatment
weighting. Direct effect of SGLT2i was estimated from

eGFR Dip in SGLT2i

a similarly weighted Cox model where the model was
additionally weighted for the inverse OR of having the
mediator in the SGLT2i group. The magnitude of effect
abrogated by the mediator was then computed from
the difference between hazard ratios (HRs) for the direct effect independent of eGFR dip and the HRs for
the total effect. Event rate differences between direct
and total effect were estimated on the basis of survival
probability, where the difference represented the difference in the rate of the outcome between the SGLT2i
and other antihyperglycemic groups that was mediated
by differences in the rate of eGFR dipping.
To assess whether the salutary association of
SGLT2i on composite cardiovascular and kidney outcomes was abrogated in SGLT2i users with a high
probability of experiencing an eGFR dip associated
with SGLT2i, we estimated the association between
SGLT2i and risk of the composite cardiovascular outcome and the composite kidney outcome in SGLT2i
users with a higher or lower than average predicted
probability of having an eGFR dip >10%, and separately eGFR dip >30%, associated with SGLT2i (ie, the
excess probability of having an eGFR dip associated
with SGLT2i compared with other antihyperglycemics
after consideration of baseline characteristics). We first
estimated the predicted baseline probability of eGFR
dip associated with covariates at treatment initiation
within the other antihyperglycemic group using logistic regression. Using results from this model, we then
computed the baseline probability of dip in the SGLT2i
group. Then, the probability of eGFR dip associated
with SGLT2i (PSGLT2i dip), conditional on the baseline
probability of dipping, was estimated within the SGLT2i
group. The SGLT2i users were then separated into
high and low risk of experiencing an eGFR dip associated with SGLT2i, based on PSGLT2i dip being above
or below the mean predicted probability. The association between SGLT2i and the risk of outcomes in users
with predicted probability of SGLT2i-related eGFR dip
higher or lower than the average probability was examined after adjusting for covariates at treatment initiation.
Association Between SGLT2i
Discontinuation and Risk of Outcomes
We then examined the association between SGLT2i
discontinuation with characteristics occurring between
treatment initiation and 6 months after treatment initiation, which included eGFR dip, adverse events, hospitalization, and HbA1c change. Logistic regression was
used and adjusted for probability of discontinuation.
The probability was estimated from a logistic regression where discontinuation was predicted by the set of
baseline covariates.
Associations between SGLT2i discontinuation and
composite cardiovascular or kidney outcomes were
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examined from Cox survival models weighted by the
inverse probability of discontinuation weight, where the
weight was constructed on the basis of the probability
of discontinuation and updated by additionally including factors that occur between treatment initiation and
6 months after treatment initiation. The effects were
estimated in all cohorts, and within those with no eGFR
dip or dip ≤10%, eGFR dip >10%, and eGFR dip >30%,
separately. The composite cardiovascular and kidney
event rates in 1 year by discontinuation and continuation of SGLT2i and their differences were calculated on
the basis of the estimated survival probabilities.
Evaluation of Potential Biases
Balance of covariates between the SGLT2i and other
antihyperglycemic group, and between SGLT2i continuation and discontinuation, was examined through
propensity score distribution and standardized difference of covariates. To test the robustness of our analyses, we tested a negative outcome control as a means
to detect the presence of spurious associations.37
Traffic-
related injury was used as the negative outcome control as there is neither biologic plausibility nor
a priori evidence suggesting the presence of a relationship with either SGLT2i use or SGLT2i discontinuation.
Other Statistical Considerations
Downloaded from http://ahajournals.org by on September 13, 2021

The 95% CIs for rate difference were generated on the
basis of 1000 times bootstrapping. A 95% CI for ratio
measure that does not cross 1 or for rate that does
not cross 0 was considered statistically significant.
All analyses were done using SAS Enterprise Guide
version 7.1 (SAS Institute, Cary, NC). The study was
approved by the Institutional Review Board of the VA
Saint Louis Health Care System, Saint Louis, MO.

RESULTS
There were 36 638 individuals in the SGLT2i group
and 209 025 individuals in the other antihyperglycemic group, corresponding to 447 399 person-years.
Among incident SGLT2i users, there were 20 458
(55.84%) with no eGFR dip, 16 180 (44.16%) with eGFR
dip >10%, and 2326 (6.35%) with eGFR dip >30%
within the first 6 months of SGLT2i initiation. Baseline
demographic and health characteristics in these
groups are provided in Table 1.

Rates of eGFR Dip in the First 6 Months
Among SGLT2i Users and Users of Other
Antihyperglycemics
Unadjusted rates of eGFR dip >10% within the first
6 months were 44.16 (95% CI: 43.66–44.67) and 30.37
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(30.17–30.56) per 100 people in the SGLT2i and other
antihyperglycemic group, respectively (Table S2). In
adjusted analyses, compared with other antihyperglycemics, excess rate of eGFR dip >10% was 9.86 (8.83–
11.0) per 100 users of SGLT2i (Figure S4). Results
showed consistently higher rates of eGFR dip >10%
in the SGLT2i group than other antihyperglycemics in
prespecified subgroups (Table S3).
Unadjusted rates of eGFR dip >30% within the
first 6 months were 6.35 (95% CI: 6.10–6.60) and 4.12
(4.03–4.20) in the SGLT2i and other antihyperglycemic groups, respectively. In adjusted analyses, the
excess rate of eGFR dip >30% attributable to SGLT2i
was small (1.15 [0.70–1.62] per 100 users of SGLT2i)
(Figure 1), and it was nonsignificant in several prespecified subgroups (Table S3).

Characteristics Associated With eGFR
Dip Among SGLT2i Users
Black race, lower eGFR category, congestive heart
failure, history of acute kidney injury, microalbuminuria,
macroalbuminuria, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use, loop diuretic
use, and nonloop diuretic use were associated with
higher risk of eGFR dip >10% and eGFR dip >30%
(Table 2).

eGFR Dip and the Effectiveness of SGLT2i
on Cardiovascular and Kidney Outcomes
To estimate whether and to what extent the protective association between SGLT2i and cardiovascular
and kidney outcomes may be abrogated by an intervening eGFR dip (conditioned on the probability
of eGFR dip), we first developed mediation analyses
where eGFR dip was considered a mediator. In analyses for the composite cardiovascular outcome, the
total effect size that accounted for eGFR dipping as
a mediator was 0.92 (95% CI: 0.84–0.99); estimates
of the association independent of eGFR dip >10%
and eGFR dip >30% yielded an HR of 0.88 (0.81–
0.92) and 0.90 (0.82–0.98), respectively, suggesting
that the magnitude of risk reduction abrogated by
eGFR dipping was 3.78% (2.22%–5.44%) and 1.18%
(0.62%–2.22%) for eGFR dip >10% and eGFR dip
>30%, respectively (Figure 2 and Table S4).
In analyses, for the composite kidney outcome, the
total effect size that accounted for eGFR dipping as a
mediator was 0.78 (95% CI: 0.71–0.87); estimates of
the association independent of eGFR dip >10% and
eGFR dip >30% yielded an HR of 0.73 (0.65–0.82)
and 0.76 (0.68–1.86), suggesting that the magnitude of
risk reduction abrogated by eGFR dipping was 4.76%
(3.17%–
6.85%) and 1.66% (0.87%–
3.01%) for eGFR
dip >10% and eGFR dip >30%, respectively (Figure 2
and Table S4).
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Table 1. Baseline Characteristics by Treatment Group and by eGFR Dip in SGLT2i Group
SGLT2i

All SGLT2i
(n=36 638)

No eGFR Dip
or Dip ≤10%
(n=20 458;
55.84%)

eGFR Dip >10%
(n=16 180; 44.16%)

eGFR Dip >30%
(n=2326; 6.35%)

65.73 (10.55)

65.30 (9.11)

64.71 (9.36)

66.06 (8.71)

66.26 (8.12)

White

145 909 (69.80)

27 169 (74.16)

15 479 (75.66)

11 690 (72.25)

1623 (69.78)

Black

39 357 (18.83)

5297 (14.46)

2685 (13.12)

2612 (16.14)

413 (17.76)

Other*

23 759 (11.37)

4172 (11.39)

2294 (11.21)

1878 (11.61)

290 (12.47)

197 727 (94.59)

35 016 (95.57)

19 529 (95.46)

15 487 (95.72)

2217 (95.31)

11 298 (5.41)

1622 (4.43)

929 (4.54)

693 (4.28)

109 (4.69)

76.05 (20.45)

78.84 (17.51)

80.77 (17.79)

75.72 (16.73)

73.38 (16.62)

Baseline Characteristics
Age, mean (SD), y

Other
Antihyperglycemics
(n=209 025)

Race, n (%)

Sex, n (%)
Men
Women
eGFR, mean (SD), mL/min per 1.73 m2
eGFR category, n (%)
eGFR ≥90 mL/min per 1.73 m2

57 407 (27.46)

10 120 (27.62)

7006 (34.25)

3114 (19.25)

342 (14.70)

90 mL/min per 1.73 m2>eGFR≥60 mL/min
per 1.73 m2

97 261 (46.53)

19 882 (54.27)

10 455 (51.10)

9427 (58.26)

1261 (54.21)

60 mL/min per 1.73 m2> eGFR≥45 mL/min
per 1.73 m2

36 044 (17.24)

5881 (16.05)

2697 (13.18)

3184 (19.68)

627 (26.96)

45 mL/min per 1.73 m2>eGFR ≥30 mL/min
per 1.73 m2

18 313 (8.76)

755 (2.06)

300 (1.47)

455 (2.81)

96 (4.13)

8.75 (1.93)

8.71 (1.37)

8.71 (1.39)

8.70 (1.34)

8.76 (1.40)

HbA1c, mean (SD), %
2

32.87 (6.53)

34.25 (6.41)

34.17 (6.41)

34.35 (6.39)

34.69 (6.58)

Low-density lipoprotein, mean (SD), mg/dL

89.97 (36.93)

80.95 (33.77)

82.10 (34.00)

79.50 (33.43)

79.05 (35.05)

Body mass index, mean (SD), kg/m
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Systolic blood pressure, mean (SD), mm Hg

132.92 (17.06)

132.35 (16.04)

131.97 (15.67)

132.82 (16.49)

133.71 (17.31)

Diastolic blood pressure, mean (SD), mm Hg

76.32 (10.43)

75.03 (9.81)

75.32 (9.73)

74.65 (9.89)

74.15 (9.89)

Congestive heart failure, n (%)

12 896 (6.17)

3416 (9.32)

1496 (7.31)

1920 (11.87)

417 (17.93)

Alcoholism, n (%)

12 148 (5.81)

1479 (4.04)

817 (3.99)

662 (4.09)

111 (4.77)

2656 (1.27)

423 (1.115)

208 (1.02)

215 (1.33)

51 (2.19)

Cancer, n (%)

42 861 (20.51)

7599 (20.74)

3986 (19.48)

3613 (22.33)

573 (24.63)

Cardiovascular disease, n (%)

1117 (48.02)

Bone fracture, n (%)

51 284 (24.53)

14 635 (39.94)

7671 (37.50)

6964 (43.04)

Diabetic ketoacidosis, n (%)

840 (0.40)

70 (0.19)

39 (0.19)

31 (0.19)

5 (0.21)

Hypoglycemia, n (%)

3855 (1.84)

1224 (3.34)

586 (2.86)

638 (3.94)

124 (5.33)

Pancreatitis, n (%)

2474 (1.18)

446 (1.22)

210 (1.03)

236 (1.46)

45 (1.93)
76 (3.27)

Bladder and urinary tract infections, n (%)

7328 (3.51)

746 (2.04)

377 (1.84)

369 (2.28)

Venous thromboembolism, n (%)

1359 (0.65)

214 (0.58)

113 (0.55)

101 (0.62)

14 (0.60)

18 821 (9.00)

3101 (8.46)

1388 (6.78)

1713 (10.59)

406 (17.45)

Acute kidney injury, n (%)
Albuminuria, n (%)
None (≤30 mg/g)
Microalbuminuria (>30–≤300 mg/g)
Macroalbuminuria (>300 mg/g)
Metformin, n (%)

88 410 (42.30)

14 414 (39.34)

8871 (43.36)

5543 (34.26)

595 (25.58)

102 139 (48.86)

18 608 (50.79)

10 053 (49.14)

8555 (52.87)

1306 (56.15)

18 476 (8.84)

3616 (9.87)

1534 (7.50)

2082 (12.87)

425 (18.27)

109 958 (52.61)

29 760 (81.23)

16 616 (81.22)

13 144 (81.24)

1876 (80.65)

Insulin, n (%)

56 150 (26.86)

20 705 (56.51)

10 892 (53.24)

9813 (60.65)

1543 (66.34)

Sulfonylureas, n (%)

61 094 (29.23)

17 734 (48.40)

9999 (48.88)

7735 (47.81)

1048 (45.06)

DPP4, n (%)

9683 (4.63)

9362 (25.56)

5298 (25.90)

4064 (25.12)

509 (21.88)

GLP1, n (%)

2921 (1.40)

4798 (13.10)

2616 (12.79)

2182 (13.49)

333 (14.32)

Thiazolidinediones, n (%)

3918 (1.87)

3081 (8.41)

1666 (8.14)

1415 (8.75)

211 (9.07)

Total No. of diabetes mellitus medications
used, mean (SD)

1.18 (0.81)

2.35 (0.93)

2.32 (0.94)

2.39 (0.92)

2.39 (0.92)

118 277 (56.59)

25 686 (70.11)

13 906 (67.97)

11 780 (72.80)

1801 (77.43)

ACEI/ARB, n (%)

(Continued)
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Table 1. Continued
SGLT2i
No eGFR Dip
or Dip ≤10%
(n=20 458;
55.84%)

Other
Antihyperglycemics
(n=209 025)

All SGLT2i
(n=36 638)

Calcium channel blockers, n (%)

56 994 (27.27)

11 133 (30.39)

5716 (27.94)

5417 (33.48)

877 (37.70)

β-Blockers, n (%)

79 898 (38.22)

18 992 (51.84)

9859 (48.19)

9133 (56.45)

1478 (63.54)

25 216 (12.06)

5970 (16.29)

2690 (13.15)

3280 (20.27)

662 (28.46)

Baseline Characteristics

eGFR Dip >10%
(n=16 180; 44.16%)

eGFR Dip >30%
(n=2326; 6.35%)

Diuretics, n (%)
Loop diuretics
Nonloop diuretics

51 521 (24.65)

9771 (26.67)

5030 (24.59)

4741 (29.30)

759 (32.63)

144 393 (69.08)

31 222 (85.22)

17 179 (83.97)

14 043 (86.79)

2066 (88.82)

Outpatient clinic

126 384 (60.46)

19 387 (52.92)

10 959 (53.57)

8428 (52.09)

1174 (50.47)

Healthcare system

82 641 (39.54)

17 251 (47.08)

9499 (46.43)

7752 (47.91)

1152 (49.53)

Statins, n (%)
Type of hospital system, n (%)

Year of treatment initial, n (%)
2016

18 247 (8.73)

746 (2.04)

412 (2.01)

334 (2.06)

35 (1.50)

2017

76 758 (36.72)

6747 (18.42)

3868 (18.91)

2879 (17.79)

388 (16.68)

2018

72 696 (34.78)

13 478 (36.79)

7608 (37.19)

5870 (36.28)

812 (34.91)

2019

41 324 (19.77)

15 667 (42.76)

8570 (41.89)

7097 (43.86)

1091 (46.90)

95 093 (45.49)

17 062 (46.57)

9555 (46.71)

7507 (46.40)

1093 (46.99)

Former

65 260 (31.22)

12 092 (33.00)

6685 (32.68)

5407 (33.42)

753 (32.37)

Current

48 672 (23.29)

7484 (20.43)

4218 (20.62)

3266 (20.19)

480 (20.64)

Smoking status, n (%)
Never
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Data are presented as mean (SD) or number (percentage). ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; DPP4,
dipeptidyl peptidase-4 inhibitor; eGFR, estimated glomerular filtration rate; GLP1, glucagon-like peptide-1 agonist; HbA1c, glycated hemoglobin; and SGLT2i,
sodium-glucose co-transporter-2 inhibitor.
*
Other race includes non-White and non-Black participants.

To determine whether the association between
SGLT2i and cardiovascular and kidney outcomes remained significant in people with higher than average
probability of experiencing an eGFR dip following
SGLT2i initiation, we tested the association in groups
based on the predicted probability of eGFR dipping
associated with SGLT2i exposure (categorized as
above and below average; where average probability
for eGFR dip >10% and eGFR dip >30% was 11.64%
and 1.92%, respectively). The results suggest that the
association between SGLT2i and cardiovascular and
kidney outcomes remained significant even in those
with higher than average probability of eGFR dip
>10% and eGFR dip >30% (Figure 3 and Table S5).
The association was also significant in those with
below average probability of eGFR dipping (Figure 3
and Table S5).

eGFR Dip and Characteristics Associated
With SGLT2i Discontinuation at 6 Months
Rates of SGLT2i discontinuation at 6 months were
21.83% in the overall SGLT2i group, and 22.10%, 20.12%,
and 29.58% in those with no eGFR dip, 10%<eGFR
dip≤30%, and eGFR dip >30%, respectively.

In analyses that balanced demographic and health
characteristics at baseline, we considered a battery of
putative characteristics that may be associated with
SGLT2i discontinuation and occurred following SGLT2i
initiation and before 6 months. eGFR dip >30%, but
not eGFR dip of 10% to 30%, was associated with
increased risk of SGLT2i discontinuation (Table S6).
The analyses also identified adverse events, including
amputation, pancreatitis, bladder and urinary tract infections, hospitalization, and HbA1c increase, as characteristics associated with increased odds of SGLT2i
discontinuation (Table S6).

Risk of Cardiovascular and Kidney
Outcomes Associated With SGLT2i
Continuation or Discontinuation at
6 Months by eGFR Dipping Category
We examined the risk of a composite cardiovascular
outcome (of nonfatal myocardial infarction, nonfatal
stroke, hospitalization for heart failure, or all-cause
mortality) associated with continued use of SGLT2i
versus discontinuation at 6 months in each eGFR
dipping category. The results suggested that compared with discontinuation, continued use of SGLT2i
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Figure 1. Adjusted rates of estimated glomerular filtration rate (eGFR) dip in the first 6 months
among users of sodium-glucose cotransporter-2 inhibitor (SGLT2i) and other antihyperglycemics.
Adjusted rates of eGFR dip >10% to 20%, >20% to 30%, and >30% in the SGLT2i group (blue) and the
other antihyperglycemic group (red); model was adjusted for covariates at treatment initiation. Error bars
represent 95% CIs.

was associated with reduced risk of cardiovascular
outcomes in nondippers, in those with eGFR dip
>10%, and in those with eGFR dip >30% (Figure 4
and Table S7).
We then examined the risk of a composite kidney
outcome (of eGFR decline >50%, end-stage kidney
disease, or all-cause mortality) associated with continued use of SGLT2i versus discontinuation in each
eGFR dipping category. The results suggested that
compared with discontinuation, continued use of
SGLT2i was associated with reduced risk of composite kidney outcome in nondippers, in those with eGFR
dip >10%, and in those with eGFR dip >30% (Figure 4
and Table S7).

Evaluation of Potential Biases
Propensity score distribution and standardized difference of covariates across treatment groups and across
discontinuation status are presented in Figures S5
through S7. Plots suggested good overlap of the propensity score across groups, and all covariates are
well balanced after weighting. A negative outcome
control was applied following the same analytic algorithm to examine if the associations observed were attributable to possible spurious biases. Traffic-related

injury, which should not causally exhibit an association with SGLT2i use or SGLT2i continuation, was used
as negative outcome control. There was no significant
association between SGLT2i and traffic-related injury
(OR: 0.96 [95% CI: 0.83–1.10]) or between SGLT2i continuation and traffic-related injury (HR: 0.93 [95% CI:
0.63–1.36]).

DISCUSSION
In this cohort study of 36 638 incident users of SGLT2i
and 209 025 incident users of other antihyperglycemics,
our results suggest that eGFR dip was more frequent
following initiation of SGLT2i than other antihyperglycemics; however, most eGFR dips were <30%. Mediation
analyses suggested that eGFR dip following initiation
of SGLT2i does not substantially abrogate the effectiveness of SGLT2i on cardiovascular and kidney outcomes. Analyses based on the predicted probability of
eGFR dipping suggested that even in those with higher
than average probability of eGFR dipping, SGLT2i use
was still associated with reduced risk of cardiovascular and kidney outcomes. Although eGFR dip <30%
was not associated with SGLT2i discontinuation, eGFR
dip >30% (a relatively infrequent event) was associated
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Table 2. Characteristics Associated With eGFR Dip Among SGLT2i Users
Adjusted Odds Ratio (95% CI)
Characteristics

eGFR Dip >10%

eGFR Dip >30%

Age

1.00 (0.99–1.00)

0.99 (0.98–0.99)

Race (reference=White)
Black

1.40 (1.31–1.49)

1.29 (1.15–1.46)

Other*

1.02 (0.95–1.09)

1.01 (0.88–1.15)

1.09 (0.98–1.21)

1.20 (0.97–1.48)

Women
2

eGFR category (reference=eGFR ≥90 mL/min per 1.73 m )
90 mL/min per 1.73 m2>eGFR≥60 mL/min per 1.73 m2

2.02 (1.91–2.14)

1.90 (1.66–2.16)

60 mL/min per 1.73 m2>eGFR≥45 mL/min per 1.73 m2

2.44 (2.26–2.63)

2.89 (2.48–3.38)

45 mL/min per 1.73 m2>eGFR≥30 mL/min per 1.73 m2

2.90 (2.46–3.41)

3.01 (2.31– 3.92)

Albuminuria (reference=no albuminuria)
Microalbuminuria (>30–≤300 mg/g)

1.22 (1.16–1.27)

1.46 (1.32–1.61)

Macroalbuminuria (>300 mg/g)

1.63 (1.50–1.76)

1.90 (1.65–2.18)

HbA1c

1.00 (0.99–1.02)

1.03 (1.00–1.06)

Low-density lipoprotein

1.00 (1.00–1.00)

1.00 (1.00–1.00)

Systolic blood pressure

1.00 (1.00–1.00)

1.00 (1.00–1.01)

Diastolic blood pressure

1.00 (0.99–1.00)

0.99 (0.99–1.00)

Congestive heart failure

1.19 (1.09–1.29)

1.30 (1.13–1.49)

Cardiovascular disease

1.04 (0.99–1.09)

1.06 (0.97–1.17)

Acute kidney injury

1.12 (1.03–1.21)

1.45 (1.28–1.65)

ACEI/ARB

1.10 (1.04–1.15)

1.22 (1.10–1.35)

Loop diuretics

1.38 (1.29–1.48)

1.70 (1.50–1.93)

Nonloop diuretics

1.29 (1.23–1.36)

1.59 (1.44–1.77)

0.98 (0.92–1.04)

0.99 (0.86–1.14)

Diuretics (reference=no diuretic use)
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Statins

Models additionally adjusted for sex, body mass index, smoking status, type of hospital system, cancer, alcoholism, hypoglycemia, diabetic ketoacidosis,
bladder and urinary tract infections, venous thromboembolism, pancreatitis, bone fracture, and history use of glucagon-like peptide-1 agonist, dipeptidyl
peptidase-4 inhibitor, sulfonylureas, thiazolidinediones, metformin, insulin, α-glucosidase inhibitors, meglitinides, amylin analogues, β-blockers, and calcium
channel blockers. ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate;
HbA1c, glycated hemoglobin; and SGLT2i, sodium-glucose co-transporter-2 inhibitor.
*
Other race includes non-White and non-Black participants.

with SGLT2i discontinuation. Compared with those
who discontinue SGLT2i in the first 6 months of therapy, and after accounting for characteristics that were
associated with discontinuation, SGLT2i continuation
was associated with reduced risk of cardiovascular
and kidney outcomes regardless of eGFR dipping.
Our findings suggest that eGFR dipping is not
uncommon following SGLT2i initiation in real-
world
setting (rate of eGFR dip >10% was 9.86 [95% CI:
8.83–11.0] per 100 users of SGLT2i); however, most
eGFR dips were <30% as rate of eGFR dip >30% was
relatively infrequent (1.15 [0.70–1.62] per 100 users of
SGLT2i). In the EMPA-REG OUTCOME (Empagliflozin
Cardiovascular Outcome Event Trial in Type 2 Diabetes
Mellitus Patients), 28.3% of empagliflozin users experienced an eGFR dip >10% and 1.4% experienced an eGFR dip of >30%.38 In the CREDENCE
(Evaluation of the Effects of Canagliflozin on Renal and
Cardiovascular Outcomes in Participants With Diabetic
Nephropathy) trial, rates of eGFR dip >10% and >30%

were 21% and 4%, respectively.4 The relatively higher
rates of eGFR dipping in these randomized trials compared with the real-world data provided in this report
are likely a reflection of the higher underlying risk of
eGFR dip among trial participants.
Our mediation analyses, which considered the contribution of an intervening eGFR dip following initiation of
SGLT2i, suggested that dipping does not abrogate the
salutary association between SGLT2i and cardiovascular
and kidney outcomes. Furthermore, our analyses suggest that even in those with higher than average probability of eGFR dipping, the association between SGLT2i
and cardiovascular and kidney outcomes remained
protective. Last, the results suggested that even after
accounting for characteristics associated with discontinuation at 6 months, continuation of SGLT2i use was
associated with reduced risk of the composite cardiovascular and kidney outcomes. Taken together, the
constellation of findings suggests that, although eGFR
dipping may be more common in SGLT2i users (than
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Magnitude of effect
abrogated by the
mediators (95% CI)

Outcome

Effect

HR (95% CI)

Composite
CVD
outcome *

Total effect accounting for
mediator
Independent of dip>10%
Independent of dip>30%

0.92 (0.84, 0.99)

Composite
kidney
outcome †

Total effect accounting for
mediator
Independent of dip>10%
Independent of dip>30%

0.78 (0.71, 0.87)

0.88 (0.81, 0.92)
0.90 (0.82, 0.98)

-3.78 (-5.44, -2.22)
-1.18 (-2.22, -0.62)

0.73 (0.65, 0.82)
0.76 (0.68, 0.86)
0.5

-4.76 (-6.85, -3.17)
-1.66 (-3.01, -0.87)
0.7
1.0
Hazard ratio

Figure 2. Risk of composite cardiovascular and kidney outcomes associated with sodium-
glucose cotransporter-
2
inhibitor (SGLT2i) (vs other antihyperglycemics) based on mediation analyses.
Mediation analyses based on inverse odds ratio weighting and adjusted for covariates measured at treatment initiation. The total effect
accounted for estimated glomerular filtration rate (eGFR) dipping as the mediator. The estimates independent of eGFR dip represent the effect
that was not mediated by eGFR dip. The magnitude of effect abrogated by the mediator was estimated from the difference between hazard
ratios (HRs) independent of eGFR dip and the HRs for the total effect and presented as a percentage. CVD indicates cardiovascular disease.
*
Composite CVD outcome of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, or all-cause mortality.
†
Composite kidney outcome of eGFR decline >50%, end-stage kidney disease, or all-cause mortality.
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other antihyperglycemics), concern about dipping should
not preclude initiation of SGLT2i. Another key message
from our analyses is that regardless of eGFR dip in the

Outcome
Composite
CVD
outcome *

first 6 months following initiation of SGLT2i, continued
use of SGLT2i may be more beneficial to long-term kidney and cardiovascular outcomes than discontinuation;
Event rate difference
per 100 patient-years
(95% CI)

Predicted
eGFR dip probability HR (95% CI)
Dip >10%

High
Low

0.89 (0.78, 0.99)
0.78 (0.64, 0.95)

-0.60 (-1.24, -0.05)
-1.30 (-2.04, -0.58)

Dip >30%

High
Low

0.84 (0.72, 0.98)
0.84 (0.72, 0.98)

-0.95 (-1.65, -0.22)
-0.88 (-1.48, -0.24)

High
Low

0.83 (0.72, 0.96)
0.66 (0.55, 0.80)

-0.86 (-1.41, -0.31)
-1.67 (-2.27, -1.03)

High
Low

0.84 (0.70, 0.99)
0.70 (0.60, 0.82)

-0.83 (-1.52, -0.05)
-1.48 (-1.96, -0.92)

Dip >10%
Composite
kidney
outcome † Dip >30%

0.5

0.7

1.0

Hazard ratio
Figure 3. Risk of composite cardiovascular and kidney outcomes associated with sodium-glucose cotransporter-2 inhibitor
(SGLT2i) (vs other antihyperglycemics) in groups based on predicted probability of SGLT2i-related estimated glomerular
filtration rate (eGFR) dip.
High and low probability of eGFR dip, categorized as above and below average predicted probability of eGFR dip associated with
SGLT2i. Average predicted probability was 11.64% and 1.92% for eGFR dip >10% and eGFR dip >30%, respectively. Model was
adjusted for covariates measured at treatment initiation. CVD indicates cardiovascular disease; and HR, hazard ratio.
*
Composite CVD outcome of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, or all-cause mortality.
†
Composite kidney outcome of eGFR decline >50%, end-stage kidney disease, or all-cause mortality.
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Event rate difference
per 100 patient-years
(95% CI)

Outcome

Group

HR (95% CI)

Composite
CVD
outcome *

Overall
No dip or dip ≤10%
eGFR dip >10%
eGFR dip >30%

0.80 (0.72, 0.88)
0.76 (0.66, 0.88)
0.84 (0.73, 0.97)
0.73 (0.55, 0.97)

-1.31 (-1.89, -0.74)
-1.34 (-2.18, -0.58)
-1.16 (-2.22, -0.20)
-3.06 (-5.81, -0.24)

Composite
kidney
outcome †

Overall
No dip or dip ≤10%
eGFR dip >10%
eGFR dip >30%

0.72 (0.63, 0.82)
0.74 (0.60, 0.91)
0.71 (0.61, 0.84)
0.70 (0.52, 0.93)

-1.06 (-1.47, -0.59)
-0.68 (-1.18, -0.16)
-1.50 (-2.27, -0.71)
-3.38 (-6.42, -0.72)

0.5

0.7
Hazard ratio

1.0

Figure 4. Risk of composite cardiovascular and kidney outcomes associated with sodium-glucose cotransporter-2 inhibitor
(SGLT2i) continuation vs discontinuation by estimated glomerular filtration rate (eGFR) dipping category.
Model adjusted for both covariates measured at treatment initiation and characteristics evaluated within 6 months after treatment
initiation. CVD indicates cardiovascular disease; and HR, hazard ratio.
*
Composite CVD outcome of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, or all-cause mortality.
†
Composite kidney outcome of eGFR decline >50%, end-stage kidney disease, or all-cause mortality.
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practitioners may consider continuation of treatment with
SGLT2i as a means of achieving longer-term reduction in
risk of cardiovascular and kidney outcomes.
Our analyses of factors associated with eGFR
discontinuation suggest that the occurrence of adverse events, hospitalization, or increase in HbA1c (a
marker of worsening glycemic control) was associated
with discontinuation of SGLT2i. Furthermore, eGFR
dip >30% was also associated with increased risk of
discontinuation. These results may be useful in guiding efforts to examine whether some of these patient
groups may benefit from resumption of treatment with
SGLT2i.39
The mechanism underpinning the eGFR dip in
SGLT2i is not entirely clear.11,40,41 It has been suggested that this initial dip is reminiscent of the mild
decline in eGFR observed in some patients following
initiation of angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker, which is generally attributed to postglomerular (efferent) vasodilatation
and reduced hyperfiltration.11,42 Several other hypotheses are being tested, including potential contribution
of enhanced proximal tubular natriuresis leading to
activation of tubuloglomerular feedback and resultant
preglomerular (afferent) vasoconstriction.11,40,41,43 The
constellation of evidence from randomized controlled
trials and real-world studies suggests that the initial
eGFR dip is likely a functional (and reversible) dip that
does not reflect kidney injury and is then followed by
eGFR stabilization, and ultimately reduced risk of adverse cardiovascular and kidney outcomes.11,17,18,41
The results of our analyses are congruent with this

understanding and support the assessment that
eGFR dip does not substantially erode the effectiveness of SGLT2i on cardiovascular and kidney outcomes, and that even in those with eGFR dip >30%,
continued therapy with SGLT2i was more beneficial
for longer-term cardiovascular and kidney outcomes
than discontinued therapy.
This study has several limitations. We used observational real-world data from the VA to build our cohort, which was mostly composed of older, White, and
male participants, which may limit the generalizability of study findings. Although our analytic approach
evaluated SGLT2i versus other active non-
SGLT2i
antihyperglycemics, considered known confounders,
and applied inverse probability weighting to generate
balance in characteristics between the 2 treatment
groups, we cannot completely rule out the possibility
of residual confounding. Although we used validated
definitions to define covariates, exposures, and outcomes based on diagnostic codes, procedure codes,
laboratory data, and pharmacy data, we cannot completely rule out misclassification. Because empagliflozin represents >97% of SGLT2i use at the VA, we
restricted our analyses to empagliflozin, and we did not
examine within SGLT2i class differences. We defined
discontinuation based on pharmacy records; hence,
the exact discontinuation date may not be accurate.
Although we estimated the probability of discontinuation by leveraging a priori knowledge through inclusion
of a comprehensive set of covariates, the direct clinical reason (or indication) of medication discontinuation
may not have been accounted for in our analyses. The
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estimation of absolute rate difference was based on
the baseline risk in our cohort, which may vary in other
populations with different baseline risks.
The study has several strengths. We used large-
scale real-world data from the VA, which operates
the largest integrated healthcare system in the United
States; VA data are captured during routine clinical
care, which might more closely recapitulate real-
world experiences.17,18,44 The selection of antihyperglycemics or discontinuation in VA was less likely
driven by financial considerations. We developed our
research aims, study design, and execution to specifically address the knowledge gap of real-
world
clinical implications of eGFR dip and the effect of
discontinuation versus continuation on clinical outcomes, which may not be addressed in randomized
controlled trials.45 In addition to reporting relative risk,
we reported absolute risk differences that may be
meaningful in informing clinical decision making.45 We
used a new user design (new SGLT2i users) with active comparator (new other antihyperglycemic users)
and applied advanced statistical methods, including
inverse probability of treatment weighting, and additionally accounted for events in the first 6 months of
therapy that may be associated with discontinuation
to evaluate the risk of outcomes in users who continue versus discontinue SGLT2i. We additionally evaluated both risk of major cardiovascular and kidney
outcomes to address questions relevant to the clinical
community. Finally, the successful testing of negative
controls, generally used to detect spurious associations, lessens concern that the observed associations
of interest may be attributable to biases.
In sum, our results suggest that eGFR dipping is
not uncommon following initiation of SGLT2i; however, most eGFR dips were <30%. The salutary
association between SGLT2i and cardiovascular
and kidney outcomes was not abrogated by eGFR
dipping. Continuation of SGLT2i (versus discontinuation) was associated with reduced risk of cardiovascular and kidney outcomes in those with no
eGFR dip, and in those with eGFR dip >10% and
eGFR dip >30%.
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Table S1. Distribution of antihyperglycemics at treatment initiation.
Medication class

Medication names

SGLT2i
Biguanide
Insulin
Sulfonylureas

Empagliflozin
Metformin
Insulin
Glyburide, Glipizide,
Glimepiride
Alogliptin, Sitagliptin,
Saxagliptin, Linagliptin
Liraglutide, Exenatide,
Semaglutide, Dulaglutide,
Lixisenatide,
Pioglitazone, Rosiglitazone
Miglitol, Acarbose

DPP4
GLP1

Distribution at
treatment initiation
36638 (14.91%)
58873 (23.96%)
33563 (13.66%)
56568 (23.03%)
31744 (12.92%)
15646 (6.37%)

Thiazolidinediones
10428 (4.24%)
Alpha-glucosidase
1902 (0.77%)
inhibitors
Meglitinides
Nateglinide, Repaglinide
283 (0.12%)
Amylin analogues
Pramlintide
18 (0.01%)
SGLT2i=sodium-glucose co-transporter-2 inhibitor. DPP4=dipeptidyl peptidase-4
inhibitor. GLP1=glucagon-like peptide-1 receptor agonist.
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Table S2. Unadjusted rate of eGFR dip>10% and dip> 30% in SGLT2i and the other antihyperglycemics
group.
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Unadjusted rate of eGFR dip>10% per
100 patients
(95% Confidence interval)
SGLT2i
Other
antihyperglycemics
Overall cohort
44.16
30.37
(43.66, 44.67)
(30.17, 30.56)
Race-White
43.03
29.7
(42.44, 43.62)
(29.47, 29.94)
Race-Black
49.31
31.42
(47.97, 50.66)
(30.96, 31.88)
Race-Other
45.02
32.69
(43.51, 46.53)
(32.10, 33.29)
eGFR≥90
30.77
22.72
mL/min/1.73 m2
(29.88, 31.68)
(22.38, 23.06)
90>eGFR≥60
47.42
31.09
mL/min/1.73 m2
(46.72, 48.11)
(30.8, 31.38)
60>eGFR≥45
54.14
34.67
mL/min/1.73 m2
(52.86, 55.41)
(34.18, 35.17)
45>eGFR≥30
60.26
42.00
mL/min/1.73 m2
(56.73, 63.70)
(41.29, 42.72)
No albuminuria
38.46
26.20
(≤30 mg/g)
(37.67, 39.26)
(25.91, 26.49)
Microalbuminuria
45.98
31.57
(>30- ≤300 mg/g)
(45.26, 46.69)
(31.28, 31.85)
Macroalbuminuria
57.58
43.65
(>300 mg/g)
(55.96, 59.18)
(42.94, 44.37)
Congestive heart
56.21
43.33
failure *
(54.54, 57.86)
(42.48, 44.19)
Acute Kidney
55.24
44.84
Injury *
(53.48, 56.98)
(44.13, 45.55)
ACE/ARB *
45.86
31.89
(45.25, 46.47)
(31.63, 32.16)
Loop diuretics *
54.94
40.93
(53.68, 56.20)
(40.32, 41.54)
Non-loop
48.52
31.90
diuretics *
(47.53, 49.51)
(31.50, 32.31)

Unadjusted rate of eGFR dip>30% per
100 patients
(95% Confidence interval)
SGLT2i
Other
antihyperglycemics
6.35
4.12
(6.10, 6.60)
(4.03, 4.20)
5.97
3.94
(5.70, 6.26)
(3.84, 4.04)
7.80
4.15
(7.11, 8.55)
(3.96, 4.36)
6.95
5.16
(6.22, 7.76)
(4.88, 5.44)
3.38
2.39
(3.04, 3.75)
(2.27, 2.52)
6.34
3.58
(6.01, 6.69)
(3.46, 3.70)
10.66
5.65
(9.9, 11.48)
(5.42, 5.89)
12.72
9.38
(10.53, 15.3)
(8.96, 9.81)
4.13
2.59
(3.82, 4.47)
(2.49, 2.70)
7.02
4.54
(6.66, 7.39)
(4.42, 4.67)
11.76
9.08
(10.75, 12.85)
(8.68, 9.50)
12.21
9.69
(11.15, 13.35)
(9.19, 10.21)
13.09
11.50
(11.95, 14.33)
(11.05, 11.96)
7.01
4.74
(6.71, 7.33)
(4.62, 4.86)
11.09
8.51
(10.32, 11.91)
(8.17, 8.86)
7.77
4.29
(7.25, 8.32)
(4.12, 4.47)

SGLT2i=sodium-glucose co-transporter-2 inhibitor. eGFR=estimated glomerular filtration rate. HbA1c=glycated
hemoglobin. ACE/ARB=angiotensin converting enzyme inhibitors/angiotensin-receptor blockers.
* Within patients with history of the disease or used the medication

Table S3. Adjusted rates of eGFR dip>10% in SGLT2i and the other antihyperglycemics group
Adjusted odds
ratio
(95% confidence
interval)

Adjusted rate per 100 patients
(95% confidence interval)
SGLT2i
Other
antihyperglycemics
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Excess rate per
100 patients
associated with
SGLT2i
(95% confidence
interval)
Overall cohort
1.54
40.65
30.79
9.86
(1.47, 1.61)
(40.11, 41.19)
(30.59, 30.98)
(8.83, 11.00)
Race-White
1.48
39.10
30.19
8.91
(1.41, 1.57)
(38.49, 39.72)
(29.96, 30.43)
(7.77, 10.01)
Race-Black
1.93
47.22
31.62
15.60
(1.72, 2.18)
(45.7, 48.74)
(31.17, 32.08)
(12.81, 18.65)
Race-Other
1.45
41.65
33.05
8.40
(1.26, 1.66)
(40.05, 43.27)
(32.46, 33.65)
(5.38, 11.88)
eGFR≥90
1.28
27.30
22.71
4.59
mL/min/1.73 m2
(1.16, 1.41)
(26.36, 28.26)
(22.37, 23.05)
(2.75, 6.51)
90>eGFR≥60
1.62
43.00
31.76
11.28
mL/min/1.73 m2
(1.53, 1.72)
(42.26, 43.74)
(31.47, 32.05)
(9.78, 12.64)
60>eGFR≥45
1.63
47.14
35.3
11.84
mL/min/1.73 m2
(1.47, 1.81)
(45.79, 48.50)
(34.81, 35.80)
(9.06, 14.75)
45>eGFR≥30
1.49
52.03
42.21
9.78
mL/min/1.73 m2
(1.13, 1.95)
(48.26, 55.79)
(41.5, 42.93)
(3.35, 16.55)
No albuminuria
1.43
33.96
26.43
7.53
(≤30 mg/g)
(1.33, 1.54)
(33.14, 34.80)
(26.14, 26.72)
(5.99, 9.20)
Microalbuminuria
1.63
43.49
32.05
11.44
(>30- ≤300 mg/g)
(1.53, 1.74)
(42.73, 44.26)
(31.76, 32.33)
(9.94, 12.91)
Macroalbuminuria
1.48
53.60
43.83
9.77
(>300 mg/g)
(1.29, 1.7)
(51.85, 55.34)
(43.11, 44.54)
(6.40, 13.09)
Congestive heart
1.41
52.02
43.55
8.47
failure *
(1.22, 1.62)
(50.27, 53.77)
(42.7, 44.4)
(5.18, 1.76)
Acute Kidney
1.30
51.81
45.20
6.61
Injury *
(1.11, 1.54)
(49.9, 53.72)
(44.49, 45.9)
(2.96, 11.04)
ACE/ARB *
1.57
42.95
32.35
10.60
(1.50, 1.66)
(42.31, 43.6)
(32.09, 32.62)
(9.27, 11.90)
Loop diuretics *
1.45
50.53
41.38
9.15
(1.30, 1.61)
(49.20, 51.86)
(40.78, 41.99)
(6.52, 12.01)
Non-loop
1.66
44.40
32.44
11.96
diuretics *
(1.53, 1.81)
(43.35, 45.46)
(32.04, 32.84)
(9.76, 13.87)
SGLT2i=sodium-glucose co-transporter-2 inhibitor. eGFR=estimated glomerular filtration rate. HbA1c=glycated
hemoglobin. ACE/ARB=angiotensin converting enzyme inhibitors/angiotensin-receptor blockers. Model
adjusted for covariates measured at treatment initiation.
* Within patients with history of the disease or used the medication

Adjusted rates of eGFR dip>30% in SGLT2i and the other antihyperglycemics group
Adjusted odds
ratio
(95% confidence
interval)

Overall cohort

1.28
(1.17, 1.41)

Adjusted rate per 100 patients
(95% confidence interval)
SGLT2i
Other
antihyperglycemics

5.40
(5.16, 5.66)

4.26
(4.17, 4.34)

Excess rate per
100 patients
associated with
SGLT2i (95%
confidence
interval)
1.15
(0.70, 1.62)

Race-White
Race-Black
Race-Other
eGFR≥90
mL/min/1.73 m2
90>eGFR≥60
mL/min/1.73 m2
60>eGFR≥45
mL/min/1.73 m2
45>eGFR≥30
mL/min/1.73 m2
No albuminuria
(≤30 mg/g)
Microalbuminuria
(>30- ≤300 mg/g)
Macroalbuminuria
(>300 mg/g)
Congestive heart
failure *
Acute Kidney
Injury *
ACE/ARB *
Loop diuretics *
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Non-loop
diuretics *

1.22
(1.09, 1.37)
1.95
(1.55, 2.47)
0.97
(0.77, 1.21)
1.18
(0.92, 1.51)
1.36
(1.20, 1.53)
1.39
(1.18, 1.64)
1.3
(0.84, 2.01)
1.19
(0.99, 1.43)
1.35
(1.19, 1.53)
1.13
(0.92, 1.39)
1.30
(1.04, 1.63)
1.00
(0.77, 1.29)
1.29
(1.16, 1.43)
1.18
(0.99, 1.40)
1.46
(1.25, 1.71)

4.93
(4.66, 5.21)
8.10
(7.31, 8.97)
5.17
(4.49, 5.95)
2.91
(2.57, 3.29)
5.03
(4.71, 5.36)
7.97
(7.26, 8.73)
11.94
(9.7, 14.61)
3.15
(2.85, 3.47)
6.24
(5.88, 6.62)
10.18
(9.17, 11.29)
12.29
(11.19, 13.49)
11.68
(10.51, 12.96)
6.22
(5.92, 6.54)
10.19
(9.41, 11.02)
6.31
(5.81, 6.84)

4.07
(3.97, 4.17)
4.32
(4.12, 4.52)
5.34
(5.07, 5.64)
2.48
(2.36, 2.61)
3.76
(3.64, 3.88)
5.85
(5.62, 6.1)
9.46
(9.04, 9.89)
2.65
(2.55, 2.76)
4.71
(4.58, 4.84)
9.1
(8.7, 9.53)
9.71
(9.21, 10.23)
11.72
(11.27, 12.18)
4.90
(4.78, 5.03)
8.79
(8.44, 9.14)
4.41
(4.24, 4.59)

0.86
(0.39, 1.36)
3.80
(2.03, 5.63)
-0.17
(-1.20, 1.02)
0.43
(-0.24, 1.16)
1.27
(0.72, 1.81)
2.11
(0.97, 3.37)
2.48
(-1.67, 6.98)
0.49
(-0.02, 1.10)
1.53
(0.84, 2.28)
1.08
(-0.67, 2.99)
2.58
(0.23, 5.00)
-0.04
(-2.36, 3.09)
1.32
(0.69, 1.97)
1.40
(-0.09, 3.24)
1.90
(1.13, 2.77)

SGLT2i=sodium-glucose co-transporter-2 inhibitor. eGFR=estimated glomerular filtration rate. HbA1c=glycated
hemoglobin. ACE/ARB=angiotensin converting enzyme inhibitors/angiotensin-receptor blockers. Model
adjusted for covariates measured at treatment initiation.
* Within patients with history of the disease or used the medication

Table S4. Risk of composite cardiovascular and kidney outcomes associated with SGLT2i (vs. other
antihyperglycemics) based on mediation analyses.
Mediator

Hazard ratio of
total effect
accounted for
mediator
(95% confidence
interval)

Composite
eGFR Dip>10%
cardiovascular
outcome *
eGFR Dip>30%

0.92
(0.84, 0.99)

Composite
Kidney
outcome †

0.78
(0.71, 0.87)

eGFR Dip>10%
eGFR Dip>30%

Hazard ratio
independent of
the mediator
(95%
confidence
interval)
0.88
(0.81, 0.92)
0.90
(0.82, 0.98)
0.73
(0.65, 0.82)
0.76
(0.68, 0.86)

Magnitude of
effect abrogated
by the mediator
(95% confidence
interval)
-3.78
(-5.44, -2.22)
-1.18
(-2.22, -0.62)
-4.76
(-6.85, -3.17)
-1.66
(-3.01, -0.87)

Mediation analyses based on inverse odds ratio-weighting for causal mediation analysis and adjusted for
covariates measured at treatment initiation.
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The total effect accounted for eGFR dipping as the mediator. The hazard ratio independent of mediator
represent the effect which was not mediated by eGFR dip. The magnitude of effect abrogated by the mediator
was estimated from the difference between hazard ratios independent of eGFR dip and the hazard ratios for
the total effect.
* Composite cardiovascular outcome was defined as non-fatal myocardial infarction, non-fatal stroke,
hospitalization for heart failure or all-cause mortality
†

Composite kidney outcome was defined as eGFR decline>50%, ESKD or all-cause mortality

Table S5. Risk of composite cardiovascular and kidney outcomes associated with SGLT2i by predicted
probability of SGLT2i related eGFR dip.
Outcomes

Composite
cardiovascular
outcome *

Composite kidney
outcome †

Group based
on probability
of eGFR dip
High probability
of dip>10%
Low probability
of dip>10%
High probability
of dip>30%
Low probability
of dip>30%
High probability
of dip>10%
Low probability
of dip>10%
High probability
of dip>30%
Low probability
of dip>30%

Adjusted hazard ratio
(95% confidence interval)
0.92
(0.85. 0.99)
0.84
(0.77, 0.93)
0.89
(0.82, 0.97)
0.89
(0.82, 0.97)
0.72
(0.65, 0.79)
0.62
(0.55, 0.69)
0.70
(0.62, 0.78)
0.66
(0.60, 0.73)

Event rate difference per
100 patient-years
(95% confidence interval)
-0.60
(-1.24, -0.05)
-1.30
(-2.04, -0.58)
-0.95
(-1.65, -0.22)
-0.88
(-1.48, -0.24)
-0.86
(-1.41, -0.31)
-1.67
(-2.27, -1.03)
-0.83
(-1.52, -0.05)
-1.48
(-1.96, -0.92)

High and low probability of eGFR dip categorized based on probability of eGFR dipping associated with
SGLT2i above or below the average, which are 11.64% for dip>10% and 1.92% for dip>30%. Model adjusted
for covariates measured at treatment initiation.
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* Composite cardiovascular outcome was defined as non-fatal myocardial infarction, non-fatal stroke,
hospitalization for heart failure or all-cause mortality
†
Composite kidney outcome was defined as eGFR decline>50%, ESKD or all-cause mortality

Table S6. Characteristics associated with discontinuation among SGLT2i users.
Prevalence (%)

eGFR dip category
No dip or dip≤10% (reference)

20454 (55.84)

10%< dip≤ 30%

13850 (37.81)

Discontinuation rate
per 100 patients *
(95% confidence
interval)

Adjusted odds ratio
(95% confidence
interval)

22.10
(21.53, 22.67)
20.12
(19.46, 20.79)
29.58
(27.72, 31.43)

1.00
0.83
(0.78, 0.87)
1.23
(1.11, 1.36)

25.10
(19.86, 30.33)
45.00
(29.58, 60.42)
31.58
(16.80, 46.36)
26.46
(23.44, 29.48)
27.46
(22.37, 32.55)
45.11
(40.83, 49.38)
24.82
(17.69, 31.95)

1.07
(0.80, 1.39)
2.85
(1.44, 5.66)
1.49
(0.73, 3.02)
1.07
(0.91, 1.26)
1.24
(0.94, 1.62)
2.58
(2.15, 3.10)
1.08
(0.73, 1.62)
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Dip> 30%

2326 (6.35)

Adverse events
Bone fracture

263 (0.72)

Amputation

40 (0.11)

Diabetic ketoacidosis

38 (0.10)

Hypoglycemia

820 (2.24)

Pancreatitis

295 (0.81)

Bladder & urinary tract
infections
Venous thromboembolism

521 (1.42)

Hospitalization not related to
adverse events

2326 (6.35)

29.58
(27.72, 31.43)

1.50
(1.33, 1.69)

Increased HbA1c

8413 (22.97)

30.81
(29.82, 31.80)

1.90
(1.80, 2.02)

141 (0.38)

Characteristics were evaluated within 6 months after treatment initiation. Model adjusted for covariates
measured at treatment initiation.
* Discontinuation rate per 100 patients within those with the characteristics

Table S7. Risk of composite cardiovascular and kidney outcomes associated with SGLT2i continuation
vs. discontinuation by eGFR dipping category.
Outcomes

Group

Composite
cardiovascular
outcome *

Overall
No dip or
dip≤10%
Dip> 10%
Dip> 30%

Composite
kidney outcome †

Overall
No dip or
dip≤10%
Dip> 10%
Dip> 30%

Adjusted
hazard ratio
(95%
confidence
interval)

0.80
(0.72, 0.88)
0.76
(0.66, 0.88)
0.84
(0.73, 0.97)
0.73
(0.55, 0.97)
0.72
(0.63, 0.82)
0.74
(0.60, 0.91)
0.71
(0.61, 0.84)
0.70
(0.52, 0.93)

Adjusted event
rate per 100
patient-years
in those who
continue
SGLT2i
(95%
confidence
interval)
5.28
(5.01, 5.59)
4.41
(4.05, 4.76)
6.43
(5.92, 6.97)
8.50
(7.00, 10.06)
2.76
(2.52, 2.98)
1.92
(1.67, 2.15)
3.85
(3.45, 4.29)
8.22
(6.82, 9.88)

Adjusted event
rate per 100
patient-years
in those who
discontinue
SGLT2i
(95%
confidence
interval)
6.58
(6.05, 7.16)
5.76
(5.09, 6.53)
7.61
(6.74, 8.54)
11.63
(9.17, 14.45)
3.81
(3.37, 4.20)
2.62
(2.09, 3.10)
5.32
(4.59, 6.09)
11.66
(9.14, 14.34)

Event rate
difference per
100 patientyears (95%
confidence
interval)

-1.31
(-1.89, -0.74)
-1.34
(-2.18, -0.58)
-1.16
(-2.22, -0.20)
-3.06
(-5.81, -0.24)
-1.06
(-1.47, -0.59)
-0.68
(-1.18, -0.16)
-1.50
(-2.27, -0.71)
-3.38
(-6.42, -0.72)
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Model adjusted for both covariates measured at treatment initiation and characteristics evaluated within 6
months after treatment initiation.
* Composite cardiovascular outcome was defined as non-fatal myocardial infarction, non-fatal stroke,
hospitalization for heart failure or all-cause mortality
†
Composite kidney outcome was defined as eGFR decline>50%, ESKD or all-cause mortality

Figure S1. Cohort construction flow.
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Figure S2. Study timeline.
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Figure S3. Analytic approach flowchart.
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Figure S4. Rates of eGFR dip in the first 6 months among users of SGLT2i and other
antihyperglycemics.
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Observed rates of eGFR dip >10 to 20%, >20 to 30% and >30% in the SGLT2i group (blue) and the other
antihyperglycemics group (red).

Figure S5a. Propensity score distribution in the SGLT2i and other antihyperglycemics groups before
weighting

Downloaded from http://ahajournals.org by on September 13, 2021

Figure S5b. Propensity score distribution in the SGLT2i and other antihyperglycemics groups after
weighting.
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Figure S6a. Propensity score distribution before weighting for those who continued and those who
discontinued SGLT2i treatment in the first 6 months.
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Figure S6b. Propensity score distribution after weighting for those who continued and those who
discontinued SGLT2i treatment in the first 6 months.
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Figure S7a. Standardized difference of covariates between the treatment groups (SGLT2i and other
antihyperglycemics) in the original cohort and the weighted cohort.
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Standardized difference below 0.1 (below the dashed line) indicated the covariate is well balanced in the
weighted cohort.

Figure S7b. Standardized difference of covariates between those who continued and those who
discontinued SGLT2i treatment in the first 6 months in the original cohort and the weighted cohort.
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Standardized difference below 0.1 (below the dashed line) indicated the covariate is well balanced in the
weighted cohort.

